In patients with inactive disease, especially in those older where MS inflammatory activity is likely low, MS should not be considered a contraindication for ICI treatment, particularly in patients with refractory malignancies and limited treatment options. In a recent study of 16 inactive MS patients, none experienced relapses or new MRI lesions following ICI treatment [[1]]. A review of 42,529 adverse events from ICI exposure through the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database identified 13 patients with MS relapses after ICI, eight of whom had pre-existing MS diagnosis. Patient #3: Brain MRI T1 post-contrast images showing enhancing lesions 2 months (3a, 3b) and 7 months (3c, 3d) after ICI initiation We describe demyelinating disease activity after ICI in a series of patients in the MS disease continuum. [Extracted from the article]